Loading clinical trials...
Loading clinical trials...
A Phase 2, Single Arm Study on Dacarbazine (DTIC) Followed by Immunotherapy Re-challenge in Unresectable or Metastatic Melanoma With Primary Resistance to PD-1/PD-L1 or PD-1 + CTLA-4 Blockade
Conditions
Interventions
Dacarbazine (DTIC)
Locations
1
Germany
University Hospital
Erlangen, Bavaria, Germany
Start Date
January 13, 2020
Primary Completion Date
January 15, 2026
Completion Date
January 15, 2026
Last Updated
February 10, 2026
NCT05689463
NCT06488950
NCT05098197
NCT06230471
NCT06671613
NCT07104149
Lead Sponsor
University of Erlangen-Nürnberg Medical School
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions